The present disclosure is directed to antibodies binding to human respiratory syncytial virus F protein, including both neutralizing and non-neutralizing antibodies, and methods for use thereof.La présente invention concerne des anticorps qui se lient à la protéine F du virus respiratoire syncytial humain, comprenant des anticorps neutralisants et non neutralisants, et leurs méthodes d'utilisation.